FOUNDATION NEWS

Join MGFA Today For Giving Tuesday Now May 5th!

Together we give.

May 5, 2020

MGFA is participating in #GivingTuesdayNow, a global day of unity in response to the unprecedented need caused by COVID-19. We have quickly adapted to address specific needs of our community, creating virtual connections for programming and support groups. If necessary, we will also create a virtual platform for our Fall walks. Please join us as we celebrate this day of unity by participating in GivingTuesdayNow and supporting our critical mission.

Subscribe to our email list.
CLICK HERE to learn more about #GivingTuesdayNow.

Ways to support MGFA:

Direct Donation
CLICK HERE to donate directly through our website. Remember, especially in these troubling times, every dollar makes a difference.

Amazon Smile
Select "Myasthenia Gravis Foundation of America National Office" as your charity of choice on smile.amazon.com. Amazon will donate 0.5% of the price of all purchases made through Amazon Smile.

Fundraise Through Facebook
CLICK HERE to create Facebook fundraiser and share it on your timeline. Encourage others to support us!

Help MGFA "Spread the Word" on Social Media
Sample messaging could include the following:
Though we cannot all get together, we can still very much give back. Join me in supporting MGFA for #GivingTuesdayNow on Tuesday, May 5. The need to support critical mission work does not stop. All donations make a difference. Thank you!

Physician-Reported Registry, CARE-MG, Captures Outcomes for those with MG and COVID-19 Infections

Subscribe to our email list.
CARE-MG, a physician-reported registry, is a joint effort of the International MG/COVID-19 Working Group and neurologists from across the globe to capture outcomes of people with MG who have developed COVID-19 infections formally launched on 09 April 2020. Robust international participation and collaboration is critical to our collective success in answering fundamental questions: Do MG patients face special risks? Do baseline therapies impact risk? Together, the two groups along with several independent experts have designed and launched this international registry.

We hope to capture outcomes in all types of myasthenia gravis (AChR, MuSK, LRP4, Seronegative) irrespective of current treatment status who have confirmed of suspected COVID-19 infection.

To learn more, please see additional information on our website here.

RESEARCH

Research Survey for Rare Disease Patients and their families about Impacts of COVID-19

Rare disease patients or their caregivers are invited to complete a 20-minute online survey from home about the ways the novel coronavirus pandemic is impacting people with rare diseases and their families.

Impacts can be related to physical health, emotional health, availability of supplies, access to care, or other problems. Your responses may help researchers understand the impacts of COVID-19 on the rare disease community.

The Rare Diseases Clinical Research Network (RDCRN) is conducting this study. The network is

Subscribe to our email list.
includes 23 research teams working to advance
diagnosis and treatment of groups of rare
diseases.

The Myasthenia Gravis Foundation of America
and Conquer MG partner with RDCRN through its
work with the Myasthenia Gravis Rare Disease Network (MGNet).

To complete the survey or learn more, visit the study page
here. Questions? Email the study team at rd.covid19@cchmc.org.

Call for Abstracts Now Open for MGFA’s 2020 Scientific
Session

The Scientific Session is an annual
meeting that provides medical professionals the opportunity to
learn about, and share work on current, pre-publication research
related to disorders of the neuromuscular junction.

To submit an abstract on research related to myasthenia gravis or
other disorders of the neuromuscular junction here. The deadline for
abstract submissions is June 11, 2020.

To view the full call for abstracts, see additional information on our
website here.

Strengthen MG Research By
Joining the MG Patient Registry

Subscribe to our email list.
As the MGFA community continues to grow, we ask each and every one of you that resides in the U.S., 18 years of age or older, to think about joining the MG Patient Registry. The registry has already made a huge difference for so many people with MG. The information you provide allows researchers to start and continue clinical trials, which leads to increased treatment options. The MG Patient Registry is an active database of individuals with myasthenia gravis (MG), developed for the purposes of research, treatment, and patient information. The registry is free to join and all data is protected by federal privacy laws.

More than 3,000 patients strong, the MG Patient Registry is the largest database to help propel research for MG. We ask you to help strengthen research and understanding about MG by joining now.

Join the MG Registry here

argenx Sponsors MyRealWorldMG International Study

MyRealWorld MG (MRW MG) is an international study assessing the impact of Myasthenia Gravis on patients' daily lives. Working with patient organizations from 9 countries (US, Japan, Germany, the UK, France, Italy, Spain, Canada, Belgium), biotechnology company argenx sponsors this innovative study.

Download the app today and share your MG journey to help researchers understand the impact and burden of MG on patients and their families.

The MyRealWorld MG study:

Subscribe to our email list.
• Is open to anyone diagnosed with myasthenia gravis, 18 years or older,
• Includes regular questionnaires and surveys about your diagnosis, your symptoms, treatments, your activities, your quality of life,
• Includes a medical profile where you can record your treatment data.

To learn more, visit www.myrealworldmg.com

AWARENESS & ALERTS

MG Walk News

The health and safety of our participants, sponsors, volunteers and staff is our top concern. All walks have been postponed until the Fall and most have been rescheduled with new dates and venues. We will continue to keep our community updated. Please understand that MGFA’s priority is the health of our patients, family members, and friends, and this has not been an easy decision to make but it has been made with your health, safety, and general well-being in

Subscribe to our email list.
Additional details can also be found on our MG Walk website [here](#).

**Sixth Annual Rare Neurological Disease Special Report Available with feature on MG**

The Rare Neurological Disease Special Report, presented by *Clinical Neurology News* and *Neurology Reviews* featured a range of articles on myasthenia gravis, from a feature on *MGNet* to FcRN therapies and more.

To view the interactive, digital issue, please see [here](#).

**“Marker of Autoimmunity Increases in U.S.”, as per National Institutes of Health article**

A study undertaken by NIH's National Institute of Environmental Health Sciences (NIEHS), investigated the presence of antinuclear antibodies, the most common marker of autoimmunity, over a 25-year period.

To learn more about this study, its findings and future studies to increase understanding of the underlying causes of autoimmune disease, please visit the NIH website here:


Subscribe to our email list.
COMMUNITY & PROGRAMMING

MGFA’s 2020 Virtual Conference Sessions and Exhibit Hall Available!

If you were not able to join us for our first virtual conference earlier this month, not to worry! You can still view all of our sessions by completing a brief, FREE registration here. After registering, you can go to the “Theatre” and click “Watch on Demand” to see all conference program sessions.

You can also still check out great information from our sponsors by

Subscribe to our email list.
the sponsor booths, which feature informative videos, downloadable handouts and more!

A very special thank you to our expert speakers, our steadfast sponsors and the MG community for making our first-ever virtual conference a resounding success. We appreciate the fun conversations and connections in our virtual lounge and the engagement in our virtual exhibit hall. We are grateful for this opportunity to bring our leadership and communities together in the spirit of caring, connecting and commitment in unprecedented times.

**NORD Launches Financial Assistance Program for Rare Disease Community**

The [National Organization for Rare Disorders (NORD)](https://www.rarediseases.org) launched a financial assistance program for rare disease community members impacted by COVID-19 earlier this month. The NORD COVID-19 Critical Relief Program provides support to rare disease patients and families facing financial challenges, helping them afford essential non-medical expenses. To learn more or to apply, please contact NORD via phone at 203-242-0497 or via email at [COVID19assistance@rarediseases.org](mailto:COVID19assistance@rarediseases.org)

**Alexion Offers MakinG Connections Webinars throughout May**

Alexion is offering live webinars through their MakinG Connections education program.

To learn more about upcoming webinars or to register: [http://alexiongmgevents.com/](http://alexiongmgevents.com/)

**UCB Expands Patient Assistance Program for those impacted by COVID-19**

The ucbCARES team is standing by and able to answer questions from
are facing hardship due to the COVID-19 pandemic and may experience difficulty affording UCB medicines due to job loss, job furlough, or loss of insurance coverage.

UCB is committed to ensuring patients, whose physicians have prescribed our medications, have uninterrupted access to their needed treatments. As such, UCB has expanded its existing Patient Assistance Program (PAP) to help eligible patients who have been impacted by COVID-19 by expediting enrollment to help ensure uninterrupted access to their medicines at no cost.

For more information, contact ucbcARES at (844) 599-CARE (2273) or by email at UCBCares@ucb.com to see if they qualify.

Myasthenia Gravis Foundation of America
myasthenia.org
1-800-541-5454 | mgfa@myasthenia.org

Share this email:

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

355 Lexington Ave 15th Floor
New York, NY | 10017 US

This email was sent to .
To continue receiving our emails, add us to your address book.